Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial.
Ito S, Takahama H, Asakura M, Abe Y, Ajioka M, Anzai T, Arikawa T, Hayashi T, Higashino Y, Hiramitsu S, Iwahashi N, Izumi C, Kimura K, Kinugawa K, Kioka H, Lim YJ, Matsuoka K, Matsuoka S, Motoki H, Nakamura S, Nakayama T, Nomura A, Sasaoka T, Takiuchi S, Toyoda S, Ueda T, Watanabe T, Yamada A, Yamamoto M, Sozu T, Kitakaze M. Ito S, et al. Among authors: kitakaze m. Sci Rep. 2023 Aug 2;13(1):12517. doi: 10.1038/s41598-023-39779-y. Sci Rep. 2023. PMID: 37532820 Free PMC article. Clinical Trial.
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.
Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M, Taguchi I, Matsunaga K, Kanzaki Y, Yoshida H, Ishizu T, Ueda S, Kitakaze M, Murohara T, Node K; PROTECT study investigators. Tanaka A, et al. Among authors: kitakaze m. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):165-172. doi: 10.1093/ehjcvp/pvac059. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36308299 Free PMC article. Clinical Trial.
DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial.
Yoshihara F, Imazu M, Sakuma I, Hiroi Y, Hara H, Okazaki O, Ishiguro C, Izumi C, Noguchi T, Shiraiwa T, Nishioka N, Fujii K, Iwakura K, Tomonaga O, Kobayashi K, Takihata M, Yumoto K, Takase H, Himi T, Shimizu I, Murakami T, Wagatsuma K, Sato K, Hiramatsu T, Akabame S, Hata S, Asakura M, Kawabata T, Omae K, Ito S, Kitakaze M; DAPPER Investigators. Yoshihara F, et al. Among authors: kitakaze m. EClinicalMedicine. 2023 Nov 27;66:102334. doi: 10.1016/j.eclinm.2023.102334. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192595 Free PMC article.
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial.
Wang X, Lam CSP, Vaduganathan M, Kondo T, Yang M, Han Y, Pham VN, Chiang CE, Kitakaze M, Miao ZM, Jhund PS, Desai AS, Inzucchi SE, de Boer RA, Martinez FA, Kosiborod MN, Hernandez AF, Claggett B, Langkilde AM, McMurray JJV, Solomon SD. Wang X, et al. Among authors: kitakaze m. JACC Asia. 2023 Dec 5;4(2):108-118. doi: 10.1016/j.jacasi.2023.10.005. eCollection 2024 Feb. JACC Asia. 2023. PMID: 38371292 Free PMC article.
Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial).
Ito S, Nakajima Y, Fukuda H, Izumi C, Nakazawa G, Yamashita H, Matsuhisa H, Inoko M, Toyoda S, Takiuchi S, Kataoka T, Izumiya Y, Abe Y, Sozu T, Sakata Y, Emoto M, Inoue T, Kitakaze M. Ito S, et al. Among authors: kitakaze m. Cardiovasc Drugs Ther. 2024 May 10. doi: 10.1007/s10557-024-07576-y. Online ahead of print. Cardiovasc Drugs Ther. 2024. PMID: 38727896
603 results